Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease.

BACKGROUND High plasma levels of coagulation factor VII have been suggested to be predictors of death due to coronary artery disease. Since polymorphisms in the factor VII gene contribute to variations in factor VII levels, such polymorphisms may be associated with the risk of myocardial infarction, which is precipitated by thrombosis. METHODS We studied a total of 444 patients, 311 of whom had severe, angiographically documented coronary atherosclerosis. Of these 311 patients, 175 had documentation of a previous myocardial infarction. As a control group, 133 patients with normal coronary arteriograms were also included. We measured the levels of activated factor VII and assessed three polymorphisms in the factor VII gene, one involving the promoter (A1 and A2 alleles), one involving the catalytic region (R353Q), and one involving intron 7. RESULTS Each of the polymorphisms influenced factor VII levels. Patients with the A2A2 and QQ genotypes had the lowest levels of activated factor VII (66 percent and 72 percent lower, respectively, than the levels in patients with the wild-type genotypes). The frequencies of the various genotypes in the patients free of coronary artery disease were similar to those in the entire population of patients with coronary artery disease. In the latter group, there were significantly more heterozygotes and homozygotes for the A2 and Q alleles among those who had not had a myocardial infarction than among those who had had an infarction (P=0.008 for the presence of the promoter polymorphism and P=0.01 for the presence of the R353Q polymorphism by chi-square analysis). The adjusted odds ratio for myocardial infarction among the patients with the A1A2 or RQ genotype was 0.47 (95 percent confidence interval, 0.27 to 0.81). CONCLUSIONS Our findings suggest that certain factor VII genotypes have a role in protection against myocardial infarction. This may explain why some patients do not have myocardial infarction despite the presence of severe coronary atherosclerosis.

[1]  M. Margaglione,et al.  Prothrombotic genetic risk factors in young survivors of myocardial infarction. , 1999, Blood.

[2]  A. Hamsten,et al.  Two common functional polymorphisms in the promoter region of the coagulation factor VII gene determining plasma factor VII activity and mass concentration. , 1999, Blood.

[3]  B. Lämmle,et al.  Coagulation factors II, V, VII, and X, prothrombin gene 20210G-->A transition, and factor V Leiden in coronary artery disease: high factor V clotting activity is an independent risk factor for myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[4]  P. Ridker,et al.  Assessment of genetic markers for coronary thrombosis: promise and precaution , 1999, The Lancet.

[5]  A. Folsom,et al.  Correlation of factor VIIa values with factor VII gene polymorphism, fasting and postprandial triglyceride levels, and subclinical carotid atherosclerosis. , 1998, Circulation.

[6]  P. Reitsma,et al.  A Genetic Propensity to High Factor VII Is not Associated with the Risk of Myocardial Infarction in Men , 1998, Thrombosis and Haemostasis.

[7]  E. Trabetti,et al.  Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. , 1998, Blood.

[8]  M. Donati,et al.  Interpretation of Thrombosis Prevention Trial , 1998, The Lancet.

[9]  P. Marckmann,et al.  Diet and blood coagulation factor VII—a key protein in arterial thrombosis , 1998, European Journal of Clinical Nutrition.

[10]  P. de Knijff,et al.  Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. , 1998, The New England journal of medicine.

[11]  A. Rumley,et al.  Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[12]  A. Arbini,et al.  The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[13]  H. Prydz,et al.  Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. de Knijff,et al.  Factor VII polymorphisms in populations with different risks of cardiovascular disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Folsom,et al.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. , 1997, Circulation.

[16]  J. Wang,et al.  Polymorphisms of factor V, factor VII, and fibrinogen genes. Relevance to severity of coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[17]  G C Overton,et al.  Functional Characterization of the Human Factor VII 5′-Flanking Region (*) , 1996, The Journal of Biological Chemistry.

[18]  D. Arveiler,et al.  Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. , 1996, Atherosclerosis.

[19]  J. Witte,et al.  Genetic dissection of complex traits. , 1994, Nature genetics.

[20]  S E Humphries,et al.  Genetic determinants of arterial thrombosis. , 1994, Bailliere's best practice & research. Clinical haematology.

[21]  P. Comp,et al.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation , 1993 .

[22]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[23]  T. Meade,et al.  A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  S. Rapaport,et al.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[26]  H. Schulte,et al.  Epidemiological Study on Factor VII, Factor VIII and Fibrinogen in an Industrial Population: I. Baseline Data on the Relation to Age, Gender, Body-Weight, Smoking, Alcohol, Pill-Using, and Menopause , 1985, Thrombosis and Haemostasis.

[27]  T. Fahey,et al.  INTERPRETATION OF THROMBOSIS PREVENTION TRIAL. AUTHORS' REPLY , 1998 .

[28]  M. Pinotti,et al.  Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[29]  G. Assmann,et al.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[30]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.